ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.34% Direct Plan: 0.43%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 19 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	134.83
AAUM (in Rs. Cr):	135.84
% of top 5 holdings:	38.95%
% of top 10 holdings:	60.71%
No. of scrips:	36

Standard Deviation^:	NA
Beta^:	NA
*Sharpe Ratio^:**	NA
Average P/B	5.75
Average P/E	47.38
Portfolio Beta	0.84
^Scheme has not completed 3 years hence NA * Risk free rate: 6.95 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	11.0960	11.5624
IDCW:	11.0960	11.5624

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	98.73
Chemicals	3.48
Vishnu Chemicals Limited	1.61
Astec LifeSciences Limited	1.15
Gujarat Fluorochemicals Limited	0.71
Diversified	0.70
TTK Healthcare Limited	0.70
Healthcare	94.55
Sun Pharmaceutical Industries Limited	14.35
Cipla Limited	7.06
Dr. Reddy's Laboratories Limited	6.07
Lupin Limited	6.05
Max Healthcare Institute Limited	5.43
Mankind Pharma Limited	4.78
Suven Pharmaceuticals Limited	4.67
Apollo Hospitals Enterprise Limited	4.45
Alkem Laboratories Limited	4.07
Aurobindo Pharma Limited	3.80
Divi's Laboratories Limited	3.61
Laurus Labs Limited	3.29
Syngene International Limited	3.28
Zydus Lifesciences Limited	2.99
JB Chemicals & Pharmaceuticals Limited	2.26
FDC Limited	2.24
Ajanta Pharma Limited	1.47
Alembic Pharmaceuticals Limited	1.45
Metropolis Healthcare Limited	1.21
Gland Pharma Limited	1.14
Vijaya Diagnostic Centre Limited	1.07
Natco Pharma Limited	1.07
Sanofi India Limited	1.04
Abbott India Limited	1.01
Rainbow Childrens Medicare Limited	0.97
Fortis Healthcare Limited	0.91
Sun Pharma Advanced Research Company Limited	0.86
Dr. Lal Path Labs Limited	0.85
Healthcare Global Enterprises Limited	0.85
Sequent Scientific Limited	0.80
GlaxoSmithKline Pharmaceuticals Limited	0.74
Ami Organics Limited	0.72
Short Term Debt & Net Current Assets	1.27

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	18.5%	19.3%	16.1%	11,841	11,927	11,606
Since Inception	5.7%	7.3%	5.8%	11,096	11,429	11,117
Direct - Growth
Last 1 Year	20.9%	19.3%	16.1%	12,088	11,927	11,606
Since Inception	8.0%	7.3%	5.8%	11,562	11,429	11,117

Past performance may or may not be sustained in future. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021) . Face Value per unit: Rs. 10.

Period	Amount Invested	Fund Value ()	Fund Returns (%)	Benchmark Value ()	Benchmark Returns (%)	Additional Benchmark Value ()	Additional Benchmark Returns (%)
Regular - Growth
Last 1 Year	1,20,000	1,38,051	29.3%	1,41,069	34.4%	1,29,901	15.8%
Since Inception	2,30,000	2,67,964	16.2%	2,72,843	18.3%	2,58,129	12.1%
Direct - Growth
Last 1 Year	1,20,000	1,39,650	32.0%	1,41,069	34.4%	1,29,901	15.8%
Since Inception	2,30,000	2,73,741	18.6%	2,72,843	18.3%	2,58,129	12.1%

Past performance may or may not be sustained in future. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).